AusperBio Secures Over $113 Million in 2025 Funding to Accelerate Development of AHB-137 for Chronic Hepatitis B Functional Cure

　　【Pharmaceutical Network Enterprise NewsOn September 22, AusperBio announced the completion of a $63 million Series B2 financing round, led by Qiming Venture Partners in collaboration with globally renowned industry investment institutions. Other participants in this round included Hanco Capital, CDH VGC, Vivo Capital, Sherpa Healthcare Partners, and Genesis Capital, among other top-tier investment firms in China.
 

Reportedly, the funds raised in this round will be mainly invested in the core development areas of AusperBio. The investments will focus on three major directions: First, accelerating the clinical trial process of its core product—AHB-137, an innovative antisense oligonucleotide (ASO) drug aimed at achieving clinical cure for chronic hepatitis B. This includes Phase III clinical trials in China, Phase II clinical trials for combination therapy and treatment-naïve patients, as well as concurrent Phase II clinical trials overseas. Second, advancing the commercialization and industrialization of AHB-137 ahead of time to lay the groundwork for successfully bringing it to market and benefiting hepatitis B patients worldwide. Third, continuously expanding the company’s innovative pipeline research and development while strengthening the construction of professional teams both domestically and internationally, accumulating core technologies and talent resources for the company's long-term growth.
 

It is worth mentioning that this is AusperBio's second round of financing completed within 2025. At the end of May this year, the company had just announced the completion of a US$50 million B+ round of financing, with investors including Qiming Venture Partners, CDH Investments, Genesis Capital, Yuanbio Venture Capital, Hansoh Capital, and Sherpa Healthcare Partners. The proceeds from this round of financing will mainly be used to support the ongoing clinical development of its innovative antisense oligonucleotide drug AHB-137 for the functional cure of chronic hepatitis B (CHB), including the planned Phase 2 clinical trials to be conducted outside mainland China. In addition, the funds will also be utilized to expand commercial production partnerships and advance the expansion of the product pipeline to facilitate the company’s long-term development. Thus far, the company's total financing amount in this year has exceeded US$113 million.
 

Public information shows that AusperBio is a clinical-stage innovative drug research and development company, focusing on the development of self-innovative targeted delivery small nucleic acid drugs, and is committed to achieving the goal of clinical cure for chronic hepatitis B.
 

The company is committed to the R&D of first-in-class and best-in-class targeted delivery small nucleic acid drugs. It focuses on the clinical cure of chronic hepatitis B (HBV) and the highly efficient targeted treatment for liver diseases, while also expanding into targeted small nucleic acid therapies for new targets beyond the liver.
 

AHB-137, a non-conjugated antisense oligonucleotide (ASO) with the potential to become a cornerstone for clinical cure of chronic hepatitis B, has garnered significant attention for its preclinical and clinical data at the European Association for the Study of the Liver (EASL 2023, 2024, 2025) and the 2024 American Association for the Study of Liver Diseases (AASLD).
 

In May this year, AusperBio announced the End-of-Treatment (EOT) data from the Phase 2b clinical trial of AHB-137 conducted in China. The results showed that in the 24-week treatment group, 75% (24/32) of the subjects reached the primary endpoint; in the 16-week treatment group, 66% (21/32) of the subjects reached the primary endpoint. Among the subjects who reached the primary endpoint, over 80% achieved HBsAg clearance within 12 weeks of treatment. At the end of treatment, 54% and 33% of the subjects in the 24-week and 16-week groups, respectively, experienced seroconversion to hepatitis B surface antibody (anti-HBs). AHB-137 demonstrated favorable efficacy and good safety in the Phase 2b clinical trial.
 

In terms of progress, on July 22, AusperBio announced that AHB-137 has been approved for Phase 3 clinical trials, marking a key step towards the goal of clinical cure for chronic hepatitis B.
 

Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice for any person.